Brace Pharma Capital
Overview
Brace Pharma Capital is a strategic investment firm formed by EMS S/A, the largest pharmaceutical company in Brazil, and high net worth biotech investors . They invest in innovative, life changing therapies for diseases with a high degree of unmet medical need and insufficient treatment options .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| HotSpot Therapeutics | May 2020 | Series B | Co-investor |
| F2G | Sep 2024 | Series H | Co-investor |
| Antiva Biosciences | Nov 2021 | Series D | - |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Brace Pharma Capital based?
Brace Pharma Capital is headquartered in Atlanta, Georgia, United States.
When was Brace Pharma Capital founded?
Brace Pharma Capital was founded in 2013.
How many portfolio companies does Brace Pharma Capital have?
Brace Pharma Capital has 4 portfolio companies in Caplight's dataset.
What are some companies in Brace Pharma Capital's portfolio?
Portfolio companies visible on Caplight include HotSpot Therapeutics, F2G, Antiva Biosciences.
What was Brace Pharma Capital's most recent investment shown here?
Brace Pharma Capital's most recent investment in this portfolio sample was in F2G in 2024.
What sectors does Brace Pharma Capital focus on?
Brace Pharma Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Brace Pharma Capital focus on?
Brace Pharma Capital typically invests at the Mid stage.
What is Brace Pharma Capital's AUM?
Brace Pharma Capital's assets under management are estimated between $50.0M and $100.0M.